Edmond de Rothschild

La Française de l'Energie S.A. engages in the exploration, production, and sell of gas resources in France. It also produces green electricity from coal bed methane gas. The company was formerly known as Française de l'Energie SAS and changed its name to La Française de l'Energie S.A. in March 2016. La Française de l'Energie S.A. was founded in 2007 and is based in Forbach, France.

Swiss Summit Capital uses a harmonic pattern recognition algorithm to provide timely stock market opportunities direct to your inbox. We rank the possible trades generated from our algorithms, and handpick what we believe offers the best risk-reward and ultimately the greatest profit potential. We simply post these trades to your inbox for you to take action. Swiss Summit Capital is powered by the Nautilus® algorithm- the result of collaboration from two industries - finance and engineering. Between them, the two authors of Nautilus have over 25 years experience in stock market trading and advanced data analytics. Combining their knowledge means that state-of-the-art analytics meets profitable trading techniques, resulting in an automated algorithm that can scour the world's markets searching for the very best investment opportunities. ​ Nautilus is a harmonic pattern recognition algorithm utilizing advanced statistical techniques. It scans thousands of global listed securities every day for price behavior patterns including: The "Gartley 222", "Butterfly", "AB=CD" (inc extensions), and Three drives", to find the most profitable trading opportunities.

Philogeris Group is a Operating accommodation facility for dependent elderly people (EHPAD) throughout the French territory.

Sapore di Mare specializes in the distribution of fish and frozen seafood products, aiming to provide consumers with healthy and flavorful food options. The company operates a network of franchise shops that focus on retail distribution, offering a unique shopping experience characterized by an innovative design and a commitment to high-quality products. By emphasizing the convenience and reliability of onboard frozen seafood, Sapore di Mare ensures that customers can enjoy a safe and appealing environment while selecting their seafood products.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Allecra Therapeutics GmbH develops pharmaceuticals to treat gram-negative multi drug-resistant bacterial infections. The company was founded in 2013 and is based in Weil am Rhein, Germany.

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Allecra Therapeutics GmbH develops pharmaceuticals to treat gram-negative multi drug-resistant bacterial infections. The company was founded in 2013 and is based in Weil am Rhein, Germany.

The SERGENT MAJOR Group distributes children’s clothing (through its historic brand name SERGENT MAJOR) and baby care items (NATALYS brand name, taken over in 2006). The Group has doubled in size in 2016 with the acquisition of the trade name Du Pareil au Même (DPAM) and now benefits from nearly 1000 shops, with 70% owned shops and 30% affiliates and outlets. Most of the shops are located in France but some are located abroad (Belgium, Spain, Italy, Germany, Middle-East).

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients